Interleukin 2 receptor blockers may directly inhibit lymphocyte mediated ischaemia reperfusion injury.
El-Asir
Layal
L
Wilson
Colin H
CH
Talbot
David
D
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D008214:Lymphocytes / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors*; D015427:Reperfusion Injury / Q000209:etiology / Q000517:prevention & control*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D015375:Receptors, Interleukin-2; D000077561:Daclizumab